By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search

Company Profile


Novartis Vaccines  

475 Green Oaks Parkway

Holly Springs  North Carolina    U.S.A.
Phone: 919-577-5000 Fax: 919-577-5197

Novartis Vaccines is a division of Novartis focused on the development of preventive treatments and is the world’s fifth-largest manufacturer and second-largest supplier of flu vaccines in the United States.

Novartis Vaccines is leading new innovation in vaccines research and manufacturing to protect health in areas of unmet medical need. The company has built a new manufacturing facility in Holly Springs, North Carolina. The state-of-the-art plant has been designed to provide 150 million adjuvanted doses of pandemic influenza vaccine within six months of declaration of an influenza pandemic.

Cell culture-derived influenza vaccines production represents the first major advancement in flu vaccine manufacturing in 50 years. Its advantages include greater speed, reliability, and flexibility in the vaccine manufacturing process.

Opportunities in Holly Springs

Novartis Vaccines has a range of opportunities in Holly Springs – from entry level to experienced, including scientists, technicians, laboratory personnel, engineers, and managers. Those who pursue their careers at the Holly Springs facility will be instrumental in meeting growing patient demand for seasonal influenza vaccines and in helping governments prepare for a possible flu pandemic. When fully operational, the Holly Springs site will provide 350 highly skilled jobs.

Novartis in Holly Springs has constructed a $36 million TD viral development lab and pilot plant. Construction is expected to be completed in early 2012.

Advancing Careers at Novartis

In order to establish itself as “an employer of choice,” Novartis has built a culture that empowers everyone to achieve technical and operational excellence with a focus on quality, safety, and customer service. The culture promotes high initiative, teamwork, mutual respect, collaboration and commitment to excellence. Novartis has been successful in attracting, retaining, and motivating employees by hiring the right people to fit the culture.

Novartis believes that its own success is directly tied to the success of its employees. Therefore, the company strives to be the best in business performance, scientific achievement, and the quality of its workplace. Novartis is proud to have been recently named the most admired pharmaceutical company in the world by Fortune, as well as on the “World’s Most Innovative Companies” list by Fast Company Magazine.

Key Statistics

Ownership: Subsidiary

Web Site: Novartis Vaccines
Symbol: NVS

Company News
Microbix Biosystems Inc. (MBXBF) Sues Novartis Vaccines and Diagnostics (NVS) For Infringement Of Its VIRUSMAX® Patent 1/7/2014 11:33:19 AM
The CementBloc and Novartis Vaccines and Diagnostics (NVS) to Jointly Present Top Considerations in Interactive Selling at the 11th Annual iPharmaConnect 3/22/2012 9:50:18 AM
Joint Research and Option for License Agreement Between NasVax Ltd. And Novartis Vaccines and Diagnostics 2/22/2010 12:26:48 PM
Novartis Vaccines and Diagnostics Begins Shipment of Fluvirin(R) Seasonal Influenza Vaccine for the U.S. Market Ahead of Schedule 8/5/2009 11:06:29 AM
Flu Vaccine Makers To Set New Doses Record For Next Season, CSL Biotherapies, Sanofi Pasteur (SASY.PA), Novartis Vaccines and Diagnostics, GlaxoSmithKline (GSK), and MedImmune Vaccines 5/12/2008 2:48:46 PM
ESBATech Starts Drug Discovery Collaboration With Novartis (NVS)10/19/2005 5:13:10 PM
Novartis (NVS) Breaks Ground On New Production Facility In Singapore10/19/2005 5:12:56 PM
Novartis Oncology (NVS) Release: First Results Of Major Study Show That Femara(R) Provides A Disease Free Survival Advantage VS. Tamoxifen In Adjuvant Treatment Of Early Breast Cancer10/19/2005 5:12:33 PM
Axentis Enterprise Helps Novartis (NVS) Gain Sarbanes-Oxley Section 404 Compliance One Year Ahead Of Deadline10/19/2005 5:12:33 PM
Inpharmatica Announces Chematica(TM) Agreement With Novartis (NVS)10/19/2005 5:12:26 PM